Sellas Life Sciences-licensed GFH009 included in trial combination for lymphoma

Sellas Life Sciences license partner GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, has entered into a clinical trial collaboration and supply agreement with BeiGene Switzerland to start a combination study of GFH009 and Brukinsa in a multicenter phase Ib/II trial treating diffuse large B cell lymphoma. In 2022, GenFleet and Sellas Life Sciences entered into an exclusive license agreement across all therapeutic and diagnostic uses worldwide outside of Greater China. The first patient was dosed in the trial. GenFleet will conduct an open-label, single-arm and multi-center study in China of the combination therapy to evaluate the safety and efficacy among relapsed/refractory DLBCL patients. Around 100,000 patients are newly diagnosed non-Hodgkin’s lymphoma per year in China, with DLBCL patients accounting for 40-50% of new cases. The trials of GFH009 treating peripheral T-cell lymphoma and acute myeloid leukemia have entered into phase II stage in China and the U.S. respectively. Numerous patients achieved complete or partial response. Preclinical research demonstrated GFH009’s anti-proliferation effects on various tumor cell lines. GFH009 has been granted with both fast track and orphan drug designation from the FDA for the treatment of adult patients with relapsed/refractory peripheral T-cell lymphomas and r/r AML.